Antiviral therapy for acute respiratory infections: the role of recombinant interferon type I


DOI: https://dx.doi.org/10.18565/pharmateca.2019.1.84-88

V.A. Bulgakova (1), E.N. Kareva (2, 3), T.E. Privalova (1, 2)

1) National Medical Research Center for Children’s Health, Moscow, Russia; 2) Pirogov Russian National Research Medical University, Moscow, Russia; 3) Sechenov First Moscow State Medical University, Moscow, Russia

Acute respiratory infections (ARI) dominate among diseases in children; over 200 different viruses can cause them. The possibilities of antiviral therapy for ARI are limited, incl. narrow spectrum of chemotherapeutic agents. The interferon system (IFN) is the main component of antiviral immune protection against ARI pathogens. Recombinant IFN-α-based preparations are active against a wide spectrum of viruses and can be used for empirical therapy of ARI. The article assesses the effectiveness of the use of nasal and rectal forms of the recombinant IFN-α2b preparation Genferon Lite for ARI and influenza in children.


For citations: Bulgakova V.A., Kareva E.N., Privalova T.E. Antiviral therapy for acute respiratory infections. Farmateka. 2019;26(1):84–88. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.1.84-88 


About the Autors


Corresponding author: Vilya A. Bulgakova, MD, Chief Researcher at the Research Prediction and Planning Laboratory, National Medical Research Center for Children’s Health, Moscow, Russia; tel. +7 (945) 967-14-20 (ext. 1467); e-mail: irvilbulgak@mail.ru
Address: 2, Build. 1, Lomonosovsky Prospect, Moscow 119991, Russian Federation


Similar Articles


Бионика Медиа